Patents by Inventor Dustin McMinn

Dustin McMinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE SALTS OF PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR
    Publication number: 20210032232
    Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.
    Type: Application
    Filed: October 9, 2020
    Publication date: February 4, 2021
    Inventors: Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
  • CDP PROTEIN SECRETION INHIBITORS
    Publication number: 20210017233
    Abstract: Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 21, 2021
    Inventors: Dustin McMinn, John William Taunton, Phillip Patrick Sharp
  • PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF
    Publication number: 20200407334
    Abstract: Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 31, 2020
    Inventors: Henry Johnson, Sean Dalziel, Dustin McMinn
  • Crystalline salts of peptide epoxyketone immunoproteasome inhibitor
    Patent number: 10836756
    Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor having a structure: Formula (I) wherein X— is a counterion, crystal forms, salts, and processes for making the same, and formulations thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 17, 2020
    Assignee: KEZAR LIFE SCIENCES
    Inventors: Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
  • Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
    Patent number: 10781192
    Abstract: Disclosed herein are methods for preparing [(2S,3R)—N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: September 22, 2020
    Assignee: KEZAR LIFE SCIENCES
    Inventors: Henry Johnson, Sean Dalziel, Dustin McMinn
  • COMBINATION THERAPY FOR IMMUNOLOGICAL DISEASES
    Publication number: 20200276204
    Abstract: Provided herein are methods of treating immune-related disorders comprising administering to a patient suffering from the disorder a therapeutically effective amount of a LMP2-selective inhibitor and a therapeutically effective amount of a LMP7-selective inhibitor. Also provided herein are compositions comprising a LMP2-selective inhibitor and a LMP7-selective inhibitor.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 3, 2020
    Inventors: Dustin McMinn, Tony Muchamuel, Henry Johnson, Eric Lowe, Janet Anderl
  • TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
    Publication number: 20200207809
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • Tripeptide epoxy ketone protease inhibitors
    Patent number: 10647744
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: May 12, 2020
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • CRYSTALLINE SALTS OF PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR
    Publication number: 20190308961
    Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor having a structure: Formula (I) wherein X— is a counterion, crystal forms, salts, and processes for making the same, and formulations thereof.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 10, 2019
    Applicant: KEZAR LIFE SCIENCES
    Inventors: Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
  • PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF
    Publication number: 20190194155
    Abstract: Disclosed herein are methods for preparing [(2S,3R)—N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.
    Type: Application
    Filed: June 29, 2017
    Publication date: June 27, 2019
    Applicant: KEZAR LIFE SCIENCES
    Inventors: Henry Johnson, Sean Dalziel, Dustin McMinn
  • Dipeptide and tripeptide epoxy ketone protease inhibitors
    Patent number: 9657057
    Abstract: Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 23, 2017
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Dustin McMinn, Henry Johnson, David C. Moebius
  • TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
    Publication number: 20160368946
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Application
    Filed: August 30, 2016
    Publication date: December 22, 2016
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • Tripeptide epoxy ketone protease inhibitors
    Patent number: 9434761
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 6, 2016
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
    Publication number: 20160031934
    Abstract: Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Dustin McMinn, Henry Johnson, David C. Moebius
  • TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
    Publication number: 20140336106
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 13, 2014
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • Benzamide derivatives and uses related thereto
    Patent number: 8772296
    Abstract: Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, and n are as defined herein.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: July 8, 2014
    Assignee: Amgen Inc.
    Inventors: Jay P. Powers, Michael Degraffenreid, Lisa Julian, Jacob Kaizerman, Dustin McMinn, Yosup Rew, Daqing Sun, Xuelei Yan, Zhulun Wang, Felix Gonzalez Lopez De Turiso
  • PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20140011796
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: September 12, 2013
    Publication date: January 9, 2014
    Applicant: AMGEN INC.
    Inventors: Michael David BARTBERGER, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason Duquette, John Eksterwicz, Benjamin Fisher, Brian Matthew Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael William Gribble, Dann James Gustin, Julie Anne Heath, Xin Huang, Xianyun Jiao, Michael Johnson, Frank Kayser, David John Kopecky, Sujen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan Dante Low, Brian Stuart Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin McMinn, Julio Cesar Medina, Jeffrey Thomas Mihalic, Steven Howard Olson, Yosup Rew, Philip Marley Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Pyridopyridazine compounds, compositions and methods of use
    Patent number: 8222251
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: July 17, 2012
    Assignee: Amgen Inc.
    Inventors: Jacob Kaizerman, Brian Lucas, Dustin McMinn, Robert Zamboni
  • PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20110319378
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 29, 2011
    Applicant: AMGEN INC.
    Inventors: Michael David BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian Matthew FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael GRIBBLE, JR., Darin James GUSTIN, Julie Anne HEATH, Xin HUANG, Xianyun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, Sujen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan Dante LOW, Brian Stuart LUCAS, Zhihua MA, Lawrence McGEE, Joel McINTOSH, Dustin McMINN, Julio Cesar MEDINA, Jeffrey Thomas MIHALIC, Steven Howard Olson, Yosup REW, Philip Marley ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU
  • Peptide epoxyketone immunoproteasome inhibitors
    Patent number: RE47302
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: March 19, 2019
    Assignee: ONYX THERAPEUTICS INC.
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius